11.01.18
Fueled, in part, by the Capsugel acquisition, Lonza posted good gains in the first half and raised expectations for the full year. Organic sales increased 8.2% during the period to $3.2 billion.
“The strong organic sales growth and margin improvements, particularly in our businesses along the healthcare continuum, helped us achieve a positive half-year 2018 result, which is why we are updating our outlook for the full year,” said Richard Ridinger, CEO of Lonza. “We look back at a successful first year after acquiring Capsugel and see that integration is progressing better than planned, operational and commercial synergies are starting to materialize and healthcare continuum offerings are becoming even stronger.”
According to Ridinger, an important part of the successful integration into the Lonza family has been the valuable contribution of Guido Driesen, Capsugel’s former CEO, who helped bring together a strong organization.
“The strong organic sales growth and margin improvements, particularly in our businesses along the healthcare continuum, helped us achieve a positive half-year 2018 result, which is why we are updating our outlook for the full year,” said Richard Ridinger, CEO of Lonza. “We look back at a successful first year after acquiring Capsugel and see that integration is progressing better than planned, operational and commercial synergies are starting to materialize and healthcare continuum offerings are becoming even stronger.”
According to Ridinger, an important part of the successful integration into the Lonza family has been the valuable contribution of Guido Driesen, Capsugel’s former CEO, who helped bring together a strong organization.